Literature DB >> 29525724

Invasive Versus Conservative Strategy in Frail Patients With NSTEMI: The MOSCA-FRAIL Clinical Trial Study Design.

Juan Sanchis1, Albert Ariza-Solé2, Emad Abu-Assi3, Oriol Alegre2, Fernando Alfonso4, José Antonio Barrabés5, José Antonio Baz3, Antonio Carol6, Pablo Díez Villanueva4, Bruno García Del Blanco5, Jaime Elízaga7, Eduard Fernandez8, Abel García Del Egido9, Joan García Picard10, Iván Gómez Blázquez11, Joan Antoni Gómez Hospital2, Rosana Hernández-Antolín12, Cinta Llibre8, Francisco Marín13, David Martí Sánchez14, Roberto Martín11, Manuel Martínez Sellés7, Gema Miñana15, María José Morales Gallardo14, Julio Núñez15, Armando Pérez de Prado9, Eduardo Pinar13, Marcelo Sanmartín12, Alessandro Sionis10, Adolfo Villa16, Jaume Marrugat17, Héctor Bueno11.   

Abstract

INTRODUCTION AND
OBJECTIVES: Although clinical guidelines recommend invasive management in non-ST-segment elevation myocardial infarction (NSTEMI), this strategy is underused in frail elderly patients in the real world. Furthermore, these patients are underrepresented in clinical trials and therefore the evidence is scarce. Our hypothesis is that an invasive strategy will improve prognosis in elderly frail patients with NSTEMI.
METHODS: This will be a prospective, multicenter, randomized trial, in which the conservative and invasive strategies will be compared in patients meeting all of the following inclusion criteria: NSTEMI diagnosis, age ≥ 70 years, and frailty defined by a category ≥ 4 in the Clinical Frailty Scale. Participants will be randomized to an invasive (coronary angiogram and revascularization if anatomically amenable) or conservative (medical treatment and coronary angiogram only if persistent clinical instability) strategy. The primary endpoint will be the number of days alive out of hospital during the first year. The coprimary endpoint will be the time until the first cardiac event (cardiac death, reinfarction or postdischarge revascularization). We estimate a sample size of 178 patients (89 per arm), considering an increase of 20% in the proportion of days alive out of hospital with the invasive management.
RESULTS: The results of this study will add important knowledge to inform the management of frail elderly patients hospitalized with NSTEMI.
CONCLUSIONS: We hypothesize that the invasive strategy will improve outcomes in frail elderly patients with NSTEMI. If this is confirmed, frailty status should not dissuade physicians from implementing an invasive management strategy. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov.Identifier: NCT03208153.
Copyright © 2018 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Acute myocardial infarction; Anciano; Elderly; Fragilidad; Frailty; Infarto agudo de miocardio

Mesh:

Year:  2018        PMID: 29525724     DOI: 10.1016/j.rec.2018.02.007

Source DB:  PubMed          Journal:  Rev Esp Cardiol (Engl Ed)        ISSN: 1885-5857


  4 in total

1.  Gender disparities in treatment response in octogenarians with acute coronary syndrome.

Authors:  Pablo Díez-Villanueva; Lourdes Vicent; Fernando Alfonso
Journal:  J Thorac Dis       Date:  2020-04       Impact factor: 2.895

Review 2.  Comparing health outcomes between coronary interventions in frail patients aged 75 years or older with acute coronary syndrome: a systematic review.

Authors:  Gregory W van Wyk; Shlomo Berkovsky; David Fraile Navarro; Enrico Coiera
Journal:  Eur Geriatr Med       Date:  2022-07-31       Impact factor: 3.269

Review 3.  Contemporary Revascularization Dilemmas in Older Adults.

Authors:  Sonali Kumar; Michael McDaniel; Habib Samady; Farshad Forouzandeh
Journal:  J Am Heart Assoc       Date:  2020-01-24       Impact factor: 5.501

4.  Prospective cohort study of elderly patients with coronary artery disease: impact of frailty on quality of life and outcome.

Authors:  Shouaib Qayyum; Jennifer Ann Rossington; Raj Chelliah; Joseph John; Benjamin J Davidson; Richard M Oliver; Dumbor Ngaage; Mahmoud Loubani; Miriam J Johnson; Angela Hoye
Journal:  Open Heart       Date:  2020-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.